Insulet Corporation
Insulet
Insulet Corporation is the pioneering developer of tubeless insulin pump technology, founded in 2000 and headquartered in Acton, Massachusetts, USA. With annual revenue of $2.71 billion in 2025 and a staggering 30.73% year-over-year growth, the company has invested over $600 million in US-based manufacturing and R&D since 2016. Insulet's flagship Omnipod 5 system is the first tubeless automated insulin delivery system that integrates with continuous glucose monitors to create a hybrid closed-loop system.
Strengths: Category-defining innovation with the world's first tubeless insulin delivery system. Hyper-growth trajectory with 30%+ annual revenue growth. Asset-heavy manufacturing strategy with $600M+ investment in US and Costa Rica production facilities. Strong market share momentum in US prescription market, now the #1 prescribed insulin pump brand. Innovative subscription model driving recurring patient revenue.
Weaknesses: Narrow product focus on a single product category (insulin pumps) creates concentration risk. Significantly smaller scale compared to Medtronic and Abbott with ~2,700 employees. Relatively limited geographic diversification outside North America. High production costs associated with domestic (US) manufacturing compared to Asian alternatives.Read More ▼Show Less ▲
Strengths: Category-defining innovation with the world's first tubeless insulin delivery system. Hyper-growth trajectory with 30%+ annual revenue growth. Asset-heavy manufacturing strategy with $600M+ investment in US and Costa Rica production facilities. Strong market share momentum in US prescription market, now the #1 prescribed insulin pump brand. Innovative subscription model driving recurring patient revenue.
Weaknesses: Narrow product focus on a single product category (insulin pumps) creates concentration risk. Significantly smaller scale compared to Medtronic and Abbott with ~2,700 employees. Relatively limited geographic diversification outside North America. High production costs associated with domestic (US) manufacturing compared to Asian alternatives.
Listed market data
PODD · NASDAQ · weeklyHistory →- Market cap
- $9.8 B
- Share price
- USD 141.10
- 1Y change
- -55.7%
- Recent change
- +0.6%
- IPO price
- +893.4%
- Revenue (TTM)
- $3 B
10-22 → 10-23
USD 15.00 · from 5/15/2007
Financial history
Full market history- 2026-10USD 141.10$9.8 B+8.1%
- 2026-09USD 130.47$8.6 B-12.2%
- 2026-08USD 148.66$9.8 B-10.1%
- 2026-07USD 165.35$10.9 B+8.6%
- 2026-06USD 152.25$10 B+5.0%
- 2026-05USD 144.94$9.5 B-15.8%
- 2026-04USD 172.14$11.3 B-18.0%
- 2026-03USD 209.84$13.8 B-14.9%
- 2026-02USD 246.61$16.2 B-3.6%
- 2026-01USD 255.81$16.8 B-10.0%
- 2025-12USD 284.24$18.7 B-13.1%
- 2025-11USD 327.19$21.5 B—
In the press
All coverage →5 latest headlines1- Bronstein, Gewirtz & Grossman (PODD) Investigation: Bronstein, Ge - The National Law Reviewnatlawreview.com2026-10-20
- Insulet stock stands 13.26 percent above its 52-week low - ad-hoc-news.dewww.ad-hoc-news.de2026-10-20
- Insulet (PODD) Rolls Out Omnipod Discover On A Narrative That May Still Be Undervalued - Simply Wall Streetsimplywall.st2026-10-20
- Medtrum Receives Favourable Ruling in French Patent Dispute with Insulet - EIN Newswww.einnews.com2026-10-20
- Full Fed. Circ. Won't Revive Insulet's $59M Trade Secrets Win - Law360www.law360.com2026-10-19
• Omnipod 5 automated insulin delivery system with SmartAdjust technology
• Omnipod DASH insulin management system with Bluetooth-enabled pod controller
• Integration with Dexcom G6/G7 and Abbott FreeStyle Libre CGM sensors
• Omnipod GO basal-only insulin delivery for type 2 diabetes patients
Digital Health – Diabetes Data Management
• Omnipod 5 mobile app for smartphone-based bolus control and monitoring
• Insulet cloud-based diabetes data analytics platform for healthcare providers
• Remote patient monitoring capabilities for healthcare system integration
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $2.7 B | $247 M |
| 2024 | $2.1 B | $418 M |
| 2023 | $1.7 B | $206 M |
| 2022 | $1.3 B | $4.6 M |
| 2021 | $1.1 B | $16.8 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Acton, Massachusetts, United States
Founded
2000
Employees
3000
Revenue
2708000000
Market cap
$9.8 B
Factories
Manufacturing facilities in Acton, Massachusetts (US) and Costa Rica
Listing
NASDAQ: PODDCategories
Related
Similar listed companies
- Nvidia Corporation· $5.2 T
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- Intel Corporation· $475 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NASDAQ: PODD , Data Sources & Methodology
Insulet Official Website
Insulet Revenue - Macrotrends
Insulet FY 2025 Results
Insulet Manufacturing Investment